Avacta Group PLC - Avacta presents data from lead candidate at AACR
Avacta Therapeutics shared Phase 1 data for FAP-Dox (AVA6000), revealing promising efficacy in salivary gland cancers without severe cardiac toxicity at the AACR Annual Meeting 2025. AVA6000 demonstrated a near doubling of progression free survival compared to benchmark data. Continued patient enrollment and further data are expected by the end of 2025.
Hemogenyx Pharma Plc - Final Results
Hemogenyx Pharmaceuticals (LSE: HEMO) announces its final audited results for the year ending 31 December 2024. The biopharmaceutical company has commenced Phase I clinical trials for its HG-CT-1 product, raised significant funds, and progressed multiple innovative therapeutic programs. The full Annual Report is available on their website.
Kefi Gold and Copper - New Member Completes Tulu Kapi Project Syndicate
KEFI Gold and Copper PLC has welcomed BCM Group as a syndicate member for the Tulu Kapi Gold Project in Ethiopia. BCM is set to contribute $23 million in pre-production costs. This collaboration ensures full project financing and alleviates KEFI's need to divest its Saudi Arabian interests.
Avacta Group PLC - Avacta presents preclinical data at AACR
Avacta Therapeutics revealed promising preclinical results for FAP-EXd (AVA6103) at the 2025 AACR Annual Meeting. The data highlights significant tumor growth inhibition and durable responses in therapy-resistant models, underscoring the potential of the pre|CISION® platform to deliver targeted, potent cancer therapies with reduced systemic toxicity.
Angle PLC - RESULTS SUPPORTING ANGLE’S HER2 ASSAY PROGRAMME
ANGLE plc announces the presentation of positive validation data for its HER2-CTC assay at the AACR Annual Meeting. The assay shows high sensitivity and specificity, identifying evolving HER2 statuses in metastatic breast cancer patients, potentially guiding targeted therapies. ANGLE's system offers a minimally invasive, real-time alternative to traditional biopsies for monitoring HER2 status changes.
Petro Matad Ltd - Signature of Oil Sales Agreement
Petro Matad Limited has signed an Oil Sales Agreement with PetroChina Daqing Tamsag for Block XX in Mongolia, covering storage, processing, transport, and export of crude oil. Invoices for production from October 2024 to March 2025 have been submitted. Future payments will be made monthly, based on the Daqing crude oil benchmark price.
Cizzle Biotechnology - Contract in Caribbean and Update on CIZ1B
Cizzle Biotechnology has announced that its partner, Cizzle Bio Inc, secured its first contract in the Caribbean, marking the extension of its licensing agreement. The deal with Doctors Hospital in the Cayman Islands initiates early royalty payments to Cizzle and reinforces plans for a broad rollout of the CIZ1B biomarker test for early lung cancer detection.
Mila Resources Plc - Drilling Campaign Update at Yarrol Gold Project
Mila Resources Plc announces progress in its drilling programme at the Yarrol Gold Project in Queensland. Three drillholes have been completed in the southern area of the license, targeting extensions beyond the historic resource. Samples have been sent to an independent laboratory, with results expected soon. Further updates will follow as the campaign advances.
80 Mile PLC - Agreement reached to drill Jameson Basin
80 Mile PLC announces a binding heads of terms agreement with March GL Company to fund stratigraphic research drilling at the Jameson project in Greenland. March GL will earn up to a 70% interest in the project upon completion of two exploration holes, while 80 Mile remains free carried until project completion. This venture highlights Jameson's energy potential.